Pliant Therapeutics to Present Data at The Liver Meeting® 2020

Rhea-AI Summary

Pliant Therapeutics, Inc. (Nasdaq: PLRX) will present a poster at The Liver Meeting® 2020, hosted by AASLD, from November 13-16, 2020. The poster, titled "Profiling Fibrosis Regression in a Rat Model of Non-Alcoholic Steatohepatitis" (Abstract #0321), will be available online for registered participants. Pliant, focused on fibrosis treatment, has two main candidates: PLN-74809, in Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and PLN-1474, in Phase 1 trials for liver fibrosis associated with NASH.

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced a poster presentation at The Liver Meeting® 2020 hosted by the American Association for the Study of Liver Diseases (AASLD) to be held virtually November 13 – 16, 2020.

Details for the poster presentation at The Liver Meeting are as follows:

Poster Title: Profiling Fibrosis Regression in a Rat Model of Non-Alcoholic Steatohepatitis (Abstract #0321)
Session: Basic Fibrosis Research and Stellate Cell Biology
Time/Date: Friday, November 13, 2020: 6:00 AM – 11:55 PM EDT

The presentation is available to registered participants via the AASLD 2020 website. The poster will be available on the Pliant Therapeutics website, under the "Our Science" section, at www.pliantrx.com on November 13.

About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of a_vß₆ and a_vß₁ integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of a_vß₁ for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, and Facebook.

Investor Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
mailto:ir@pliantrx.com

Media Contact:
Cambria Fuqua
Canale Communications
cambria.fuqua@canalecomm.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/pliant-therapeutics-to-present-data-at-the-liver-meeting-2020-301168419.html

SOURCE Pliant Therapeutics, Inc.

FAQ

When is Pliant Therapeutics presenting at The Liver Meeting 2020?

Pliant Therapeutics will present from November 13 to 16, 2020.

What is the title of Pliant Therapeutics' poster presentation?

The poster is titled "Profiling Fibrosis Regression in a Rat Model of Non-Alcoholic Steatohepatitis".

What is the stock symbol for Pliant Therapeutics?

The stock symbol for Pliant Therapeutics is PLRX.

Where can I find the poster from Pliant Therapeutics' presentation?

The poster will be available on Pliant's website under the "Our Science" section starting November 13, 2020.

What are the main products in development by Pliant Therapeutics?

Pliant's main candidates are PLN-74809 for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and PLN-1474 for liver fibrosis associated with NASH.